Genetics of IL28B and HCV--response to infection and treatment (Q38013941)

27 August 2017

title

Genetics of IL28B and HCV--response to infection and treatment (English)

1 reference

27 August 2017

4

Kazuaki Chayama

1 reference

27 August 2017

2

Michio Imamura

1 reference

27 August 2017

3

Hiroshi Aikata

1 reference

27 August 2017

1

C Nelson Hayes

1 reference

27 August 2017

language of work or name

English

0 references

publication date

29 May 2012

1 reference

Nature Reviews Gastroenterology & Hepatology

27 August 2017

published in

1 reference

27 August 2017

volume

9

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

406-417

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Telaprevir: a new hope in the treatment of chronic hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interferon- Is Functionally an Interferon but Structurally Related to the Interleukin-10 Family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interleukin-28B Acts Synergistically With Cisplatin to Suppress the Growth of Head and Neck Squamous Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B inhibits hepatitis C virus replication through the JAK–STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

The role of transposable elements in the regulation of IFN-lambda1 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B single nucleotide polymorphisms in the treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B Genotype Effects During Early Treatment with Peginterferon and Ribavirin in Difficult-to-Treat Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interferon signaling and treatment outcome in chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Association of IL28B variants with response to pegylated‐interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Dysregulation of IFN System Can Lead to Poor Response to Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

VISA is an adapter protein required for virus-triggered IFN-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Expert opinion on the treatment of patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

In the Absence of HCV Infection, Interferon Stimulated Gene Expression in Liver Is Not Associated With IL28B Genotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

The human genome browser at UCSC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.101

Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22641049

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2012.101

1 reference

27 August 2017

1 reference